Streetbeat News

TSVT

2seventy bio, Inc.

https://www.2seventybio.com

Industry

Biotechnology

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Open

4.95

Mkt cap

255M

Volume

High

4.96

P/E Ratio

-2.70

52-wk high

5.99

Low

4.94

Div yield

N/A

52-wk low

2.29

Trading for TSVT was halted at 1:00:00 p.m. ET due to pending news. The halt is a temporary measure until the news affecting the company is released.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 5:00 pm

Cardlytics, Inc. (CDLX) shares surged by approximately 37% in pre-market trading after reporting Q4 earnings that exceeded expectations, with adjusted earnings of 14 cents per share against estimates of 12 cents. The company also forecasted Q1 revenue between $70 million and $73 million, surpassing the expected $66.46 million. Other stocks showed significant movement in pre-market trading, with notable gainers including Fisker Inc. (FSR), Madrigal Pharmaceuticals, Inc. (MDGL), and American Vanguard Corporation (AVD), among others. Conversely, companies like Kopin Corporation (KOPN), Smartsheet Inc. (SMAR), and Adobe Inc. (ADBE) experienced declines.

Portfolio Pulse from Avi Kapoor

March 15, 2024 | 12:13 pm

Morgan Stanley initiates Arcellx Inc (ACLX) with an Overweight rating and a price target of $81, highlighting its lead asset ddBCMA's potential to outperform Bristol-Myers Squibb (BMY) and Johnson & Johnson's (JNJ) multiple myeloma cell therapies. ddBCMA's differentiated design is expected to offer advantages in transduction efficiency and stability. Collaboration with Gilead Sciences (GILD) aims to overcome manufacturing challenges. Arcellx's ddBCMA could capture up to 46% of the market by 2026 if approved.

Portfolio Pulse from Vandana Singh

March 07, 2024 | 7:52 pm

2seventy bio (NASDAQ:TSVT) reported Q4 earnings with a loss of $(1.11) per share, missing the $(0.99) estimate, and sales of $10.68M, missing the $14.71M estimate. This represents an 85% decrease in EPS and an 80.98% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:04 pm

Earnings reports for March 5, 2024, include a mix of expected quarterly losses and earnings from various sectors. Notable companies like NIO, Target, and Nordstrom are among those reporting. The reports span across different industries, including automotive, retail, biotech, and technology, indicating a broad market impact.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 10:00 am

2seventy bio (NASDAQ:TSVT) is scheduled to release its quarterly earnings report on March 5, 2024, with analysts expecting an EPS of $-0.99. The company's past earnings performance shows a mixed record of beating and missing EPS estimates, with share price reactions varying accordingly. Shares have been trading at $5.64 as of March 1, down 51.88% over the last 52 weeks, indicating potential investor concern ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 4:02 pm

The FDA's Oncologic Drugs Advisory Committee is set to review Bristol Myers Squibb and 2Seventy Bio's supplemental application for Abecma, aimed at treating triple-class exposed relapsed or refractory multiple myeloma, in a virtual meeting on March 15.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:02 pm

Regeneron Pharmaceuticals Inc (REGN) reported a Q4 adjusted EPS of $11.86, surpassing estimates and showing a revenue increase of 1% to $3.43 billion. Dupixent sales, recorded by Sanofi (SNY), rose 31% to $3.22 billion. Regeneron's Eylea sales slightly declined, while Libtayo sales surged 44%. Additionally, Regeneron formed Regeneron Cell Medicines after acquiring assets from 2seventy bio Inc (TSVT), with REGN shares rising 3.26% in premarket trading.

Portfolio Pulse from Vandana Singh

February 02, 2024 | 4:08 pm

Advanced Micro Devices, Inc. (AMD) shares fell 3.8% to $165.49 post Q4 earnings report, with non-GAAP EPS of $0.77 on $6.17 billion revenue. Other stocks showed significant movement: Connexa Sports Technologies Inc. (CNXA) regained Nasdaq compliance, surging 204%; Minim, Inc. (MINM) rose 76.4% after a stake disclosure; Powell Industries, Inc. (POWL) gained 49% on strong Q1 results and dividend raise. Notable losers included Nuvve Holding Corp. (NVVE) dropping 65.8% after a public offering announcement, and New York Community Bancorp, Inc. (NYCB) falling 34.5% on disappointing Q4 results and dividend cut.

Portfolio Pulse from Avi Kapoor

January 31, 2024 | 6:18 pm

2seventy Bio's stock is trading higher following an upgrade by Leerink Partners from Market Perform to Outperform, with a significant increase in the price target from $5 to $18.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 5:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.